ADVR and ONLY ADVR Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KAKALAK who started this subject	9/25/2000 2:17:52 PM
From: Kingfisher	Read Replies (3) of 278

As most of you already know there has been another wallstreetreporter interview this morning at the following URL: wallstreetreporter.com Here are a couple of my thoughts from listening to this interview: 1. There appeared to be a deliberate refusal on the part of Dr. Hirschman not to say the word Reticulose, always referring to the ADVR flagship drug as Product R. I did not observe this in the previous interviews but it may have occurred there also. However, with the pending Michigan Federal court hearing coming up it may be a deliberate action on his part to sort of disassociate with Reticulose. [This thought could be far fetched on my part.] BTW, I believe that the NY Court litigation as been dismissed without prejudice. 2. Also, there seemed to be a deliberate refusal on the part of Dr. Hirschman to mention anything concerning ADVR expectation as to the date/month for the INDA submission. [In a way I feel that this action on his part should be expected since it could have sort of hyping to the stock.] All in all nothing new or overly exciting by this interview.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next